Seres Therapeutics (MCRB) Achieves Target Enrollment of SER-109 Phase 2 Study
Tweet Send to a Friend
Seres Therapeutics, Inc. (NASDAQ: MCRB) announced today that the target enrollment of 87 patients has been achieved for its ongoing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE